Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

NCT ID: NCT02485717

Last Updated: 2021-05-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 291 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-05-02
• Study Completion Date: 2018-06-25

Brief Summary

To assess the safety and efficacy of Natroba (spinosad) topical suspension versus placebo for the clinical cure of scabies after a single treatment. The trial will also assess the pharmacokinetics (PK) of spinosad and benzyl alcohol following a single dose of Natroba™ in pediatric subjects 4-16 years of age. These subjects will be a separate population of pediatric subjects.

Detailed Description

The primary study is a double blind, two-arm, 28-day, placebo-controlled study with approximately 120 infested "index" subjects randomized 1:1 to Natroba™ or Placebo. All members of a household (no more than 6 individuals) with a suspected "index" subject must be screened at the first visit. In this study, "index" subjects are defined as the youngest infested household member (≥4 years). If the members have an active scabies infestation and meet all other criteria, they must agree to participate in the study. Household members who do not present with scabies at the screening visit must also agree to apply the same blinded investigational product (IP) as household members who present with scabies. All household members must agree to participate in the study or none will be enrolled. Screening procedures include informed consent, medication and medical history, urine pregnancy test for females of childbearing potential, scabies assessment (visual evidence of burrows, inflammatory/non-inflammatory lesions and pruritus), microscopic examination of skin scraping, or dermatoscopy, to demonstrate the presence of mites, eggs, and/or scybala (dermatoscopy must confirm burrows), vital signs, general skin and eye assessment, randomization, CBC and serum chemistry, and IP dispensing and instruction.

After screening on Day 1, all randomized subjects in the primary population will be dispensed IP (Natroba™ or Placebo) to apply at home later the same day as a single treatment over the entire body from the neck down to the toes (including the soles of the feet) and to the scalp (if balding) or hairline, temples and forehead on the same day. Subjects less than 12 years of age should be assisted with administration by a parent, guardian or caregiver. Subjects will rub the treatment into the skin followed by a 10-minute wait period before getting dressed. Showering or bathing must not occur earlier than 6 hours after treatment and no later than at least 1 hour prior to Day 2 visit.

A separate population of 24 pediatric "non-index" subjects that do not reside in the "index" subject's household will be enrolled to assess the PK of spinosad and benzyl alcohol for 12 hours after open-label topical application on a single in-clinic visit (Day 1, or Day 2 if screening only on Day 1). There will be 12 male or female subjects 4 - 9 years of age (with a minimum of 6 male or female subjects 4 - 6 years of age) and 12 male or female subjects 10 - 16 years of age. With assistance from a caregiver, Natroba™ will be applied over entire body from the neck down to the toes (including the soles of the feet) and to the hairline, temples, and forehead. The open-label product will remain on the skin for at least 6 hours before bathing or showering. The subjects will stay in the clinic until the 12-hour procedures are completed. Blood draws will be taken at 0 hours just prior to treatment, and then at 0.5, 1.0, 3.0, 6.0 hours post-treatment and then at 12 hours post-treatment. Bathing must occur after the 6 hour blood draw but prior to the 12 hour blood draw. A ±5 minute time window will be allowed for all post-treatment blood samples. Safety will be assessed with adverse events (AEs), general skin and eye irritation assessments, pre-dose and pre-discharge laboratory evaluations, and vital signs during the 12 hours in-clinic. Following the sample collections subjects will be released from the clinic and directed to their primary care physician for follow-up. PK subjects will be provided 5% Permethrin upon discharge to dispense to household members.

In the primary population (all household members), on Day 2 (Visit 2), general skin and eye assessments will be made for possible irritation, and to confirm that all IP was left on for a minimum of 6 hours before bathing or showering. If a subject reports an adverse event assessed as related by the PI on Day 2 (Visit 2) then a follow-up visit with the investigator must be scheduled within 7 days of visit. Subjects will receive a well-being phone call on Day 14 to continue to emphasize instructions to prevent re-infestation, determine if any concomitant medications have been used, and check for adverse events. If a subject reports an adverse event assessed as related by the PI on the Day 14 well-being phone call, then a follow-up visit with the investigator must be scheduled within 7 days of phone call.

On Day 28 (Visit 3), all household members will return to the clinic for safety and efficacy assessments. The primary endpoint of complete cure will be assessed in the infested household members. If the infested subject is completely cured at Day 28, he or she will have completed the study and termination procedures will be conducted. If the subject is not completely cured at Day 28 (with Natroba™ or Placebo), the subject will receive 5% Permethrin and will be directed to their primary care physician for follow-up.

Safety assessments will be made for all household members and will include monitoring of adverse events (AEs) throughout the study, vital signs recording (Days 1 and 28), clinical laboratory analyses (Days 1 and 28), and general skin and eye irritation assessments (Days 1, 2, and 28).

The Day 28 procedures will also be completed for early termination (ET) except subjects will not receive rescue Permethrin, but will be directed to follow-up with their primary care physician.

Conditions

Scabies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Natroba (spinosad)

spinosad topical suspension, 0.9% up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours

Group Type: EXPERIMENTAL

spinosad topical suspension, 0.9%

Intervention Type: DRUG

Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Placebo

placebo is a topical suspension that is the same formulation as Natroba without the active ingredient spinosad. Up to 120 mL (enough product is used to cover the body from the neck down to the soles of the feet), one treatment left on for 6 hours.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Interventions

spinosad topical suspension, 0.9%

Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Intervention Type: DRUG

Placebo

Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Intervention Type: OTHER

Other Intervention Names

Natroba (spinosad) Topical Suspension, 0.9%

Eligibility Criteria

Inclusion Criteria

• All household members who have provided written informed consent and an authorization for disclosure of protected health information must meet all the following criteria:

1. Male or female, age 4 years and upward.

2. At least one household member must have active scabies infestation confirmed by clinical signs and symptoms (evidence of burrows or presence of scabies inflammatory/non-inflammatory lesions and pruritus) as well as by microscopic examination of skin scraping, or dermatoscopy, to demonstrate the presence of mites, eggs, and/or scybala. If dermatoscopy is used it should also confirm there are burrows on the skin.

3. Generally in good health based on medical history and clinical assessments.

4. Normal-appearing skin in noninfested areas.

5. No history of chronic or recurrent dermatologic disease.

6. Willingness to comply with the study procedures including blood collections and application of study treatment at home or in-clinic (PK subjects).

7. Willing and able to practice an acceptable measure of contraception during the study, if female of childbearing potential. Examples of acceptable contraceptive methods include abstinence, intrauterine device (IUD) or double barrier method, oral or injectable contraceptives (must have been using consistent systemic contraceptives for at least 3 months prior to enrollment). If abstinent and planning to become sexually active with a household member must agree to use a double barrier method.

8. Subject agrees to inform their sexual partners to seek an examination for scabies and treatment if, and when, symptoms present.

9. Household members must be 6 or fewer and all members must be willing to attend clinic visits and be randomized to treatment (blinded, but same for all).

Exclusion Criteria

• All household members must be excluded if any of the following conditions are met:

1. Household has greater than 6 residents.

2. Has a household member(s) who is not willing or not eligible to enroll.

3. Presence of scabies on the scalp.

4. Presence of crusted scabies (Norwegian scabies).

5. Allergies or intolerance to ingredients in the IPs.

6. Current pregnancy (as assessed by urine pregnancy test) or currently nursing.

7. The household has sexually active subjects who do not agree to restrict prolonged skin to skin contact with non-household members during the trial period.

8. Known renal or hepatic impairment.

9. Treatment with scabicide within the prior 4 weeks.

10. Immunodeficiency (including HIV infection) as reported in Medical History.

11. Signs or symptoms of systemic infection.

12. Administration of systemic therapy for infectious disease within the prior 2 weeks.

13. Receipt of any IP within the prior 4 weeks.

14. Any other conditions that, at the investigator's discretion, may interfere with the study conduct, or which might confound the interpretation of the study results, or which may put the subject at undue risk.

15. Does not have a known household affiliation with their household members (stays in one household inconsistently, i.e., sleeps at one place several nights and then other places on other nights).

16. Household member is unwilling to treat scabies.

• Minimum Eligible Age: 4 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Concentrics Research

OTHER

Sponsor Role: collaborator

ParaPRO LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Kerry W Mettert, MBA

Role: STUDY_DIRECTOR

ParaPRO LLC

Locations

Elk Grove Clinical Research

Elk Grove, California, United States

The Chappel Group Research

Kissimmee, Florida, United States

San Marcus Research

Miami, Florida, United States

L&C Professional Medical Research Institute

Miami, Florida, United States

LSRN Research

West Palm Beach, Florida, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

SPN-303-15

Identifier Type: -

Identifier Source: org_study_id